Idexx Laboratories (IDXX) Income from Continuing Operations (2009 - 2026)

Idexx Laboratories' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 278446000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 14.74% year-over-year to 278446000.0; the TTM figure through Mar 2026 stood at 1095233000.0 (up 22.38% YoY), while the FY2025 annual figure was 1059464000.0, up 19.33% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 278446000.0, up from 248188000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 293989000.0 in Q2 2025, with the low at 131979000.0 in Q2 2022.
• The 5-year median for Income from Continuing Operations is 216149000.0 (2024), against an average of 220582823.53.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 34.86% in 2022, then surged 69.9% in 2023.
• Idexx Laboratories' Income from Continuing Operations stood at 172207000.0 in 2022, then advanced by 12.96% to 194521000.0 in 2023, then grew by 11.12% to 216149000.0 in 2024, then advanced by 14.82% to 248188000.0 in 2025, then rose by 12.19% to 278446000.0 in 2026.
• Business Quant data shows IDXX's Income from Continuing Operations at 278446000.0 in Q1 2026, 248188000.0 in Q4 2025, and 274610000.0 in Q3 2025.